10.05.26 -- CDMOs Co-Author The RNA Ecosystem

Delve into the complexities of scaling decisions to gain insights from biopharma developers and a CDMO. Learn about their mutual interest in achieving successful scale-up and strategies.

As demand for GLP-1s and biologics accelerates, it's become crucial that pharmaceutical companies stay competitive and bring therapies to market faster by partnering with a CDMO.

Modern sterile manufacturing requires proactive quality risk management. Robust contamination control across facilities, processes, and supply chains supports compliance and patient safety.

How robotic, gloveless fill‑finish cuts aseptic risk, enables flexible containers, and scales manufacturing—connecting advanced automation to patient safety and operational efficiency.

Aligning visual inspection systems with site standards prevents costly validation failures. Discover strategies to de-risk equipment startup.

Learn how process design and cross-functional collaboration mitigate risks and accelerate the path from early development to FIH manufacturing through real-world case studies of practical approaches.

Nose‑to‑brain delivery enables targeted neurological treatment by using direct neural pathways to boost precision and limit systemic exposure, with new formulations and devices driving rapid progress.

See how continuity planning, technology transfer capabilities, global network flexibility, and digital visibility contribute to resilient supply chains and help protect programs from disruption.

Watch how biopharmaceutical leaders address scalability, quality control, and regulatory challenges when manufacturing protein-based therapies at commercial scale.

Use a gene expression system that allows you to produce molecules that are 100% free of fucose and demonstrate increased potency, without compromising on titers, growth, stability, or product quality.